Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection
Тенектеплаза при инсульте через 4,5–24 часа с отбором пациентов по данным перфузионной визуализации
2024-02-08
SCID: 54.1/drk6zh74
Discuss with AI
late-window ischemic strokemiddle cerebral artery occlusionmodified Rankin Scaleperfusion imagingtenecteplase
Figures from the paper
Abstract (AI)
BACKGROUND: Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. METHODS: We conducted a multicenter, double-blind, randomized, placebo-controlled trial involving patients with ischemic stroke to compare tenecteplase (0.25 mg per kilogram of body weight, up to 25 mg) with placebo administered 4.5 to 24 hours after the time that the patient was last known to be well. Patients had to have evidence of occlusion of the middle cerebral artery or internal carotid artery and salvageable tissue as determined on perfusion imaging. The primary outcome was the ordinal score on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability and a score of 6 indicating death) at day 90. Safety outcomes included death and symptomatic intracranial hemorrhage. RESULTS: The trial enrolled 458 patients, 77.3% of whom subsequently underwent thrombectomy; 228 patients were assigned to receive tenecteplase, and 230 to receive placebo. The median time between the time the patient was last known to be well and randomization was approximately 12 hours in the tenecteplase group and approximately 13 hours in the placebo group. The median score on the modified Rankin scale at 90 days was 3 in each group. The adjusted common odds ratio for the distribution of scores on the modified Rankin scale at 90 days for tenecteplase as compared with placebo was 1.13 (95% confidence interval, 0.82 to 1.57; P = 0.45). In the safety population, mortality at 90 days was 19.7% in the tenecteplase group and 18.2% in the placebo group, and the incidence of symptomatic intracranial hemorrhage was 3.2% and 2.3%, respectively. CONCLUSIONS: Tenecteplase therapy that was initiated 4.5 to 24 hours after stroke onset in patients with occlusions of the middle cerebral artery or internal carotid artery, most of whom had undergone endovascular thrombectomy, did not result in better clinical outcomes than those with placebo. The incidence of symptomatic intracerebral hemorrhage was similar in the two groups. (Funded by Genentech; TIMELESS ClinicalTrials.gov number, NCT03785678.).
Key Findings
1
A multicenter, double-blind randomized trial evaluated tenecteplase 4.5–24 hours after stroke onset in patients with large-artery occlusion and salvageable tissue on perfusion imaging.
2
Among 458 patients, 77.3% underwent thrombectomy; tenecteplase was administered to 228 patients and placebo to 230.
3
Median 90-day modified Rankin Scale scores were 3 in both treatment groups.
4
Mortality and symptomatic intracranial hemorrhage were numerically higher with tenecteplase than placebo: 19.7% versus 18.2% and 3.2% versus 2.3%, respectively.
5
Tenecteplase did not significantly improve 90-day functional outcomes compared with placebo, with an adjusted common odds ratio of 1.13 (95% CI, 0.82–1.57; P=0.45).
Research Object
Patients with ischemic stroke caused by middle cerebral artery or internal carotid artery occlusion and salvageable tissue 4.5 to 24 hours after they were last known to be well
Research Subject
The efficacy and safety of delayed tenecteplase therapy, assessed by 90-day functional outcome, mortality, and symptomatic intracranial hemorrhage
Publication Details
Publication Date
2024-02-08
Journal
Publisher
ISSN
Cited by
237
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association2019
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke2014
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke2015
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke2015
Cited by12
2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association2026
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy2024
Efficacy and Safety of Intravenous Thrombolysis in the Extended Time Window for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis2025
Safety and efficacy of intravenous thrombolytic therapy in the extended window up to 24 hours: A systematic review and meta‐analysis2024
Advances in intravenous thrombolysis with tenecteplase in the ultra-time window2026
DWI-FLAIR mismatch versus perfusion-based selection for extended window thrombolysis in acute ischemic stroke: a meta-analysis of randomized controlled trials2026
Gray zones in acute stroke reperfusion: bridging, distal medium vessel occlusion, and extended-window thrombolysis2026
Extending the Treatment Window for Intravenous Thrombolysis in Acute Ischemic Stroke: An Updated Systematic Review and Meta-Analysis2026
Tenecteplase in the Extended 4.5–24-Hour Window for Acute Ischemic Stroke: An Updated Meta-Analysis of RCTs with EVT-Stratified Subgroup Analysis2026
Safety and efficacy of intravenous tenecteplase in patients with acute ischemic stroke in extended time window: systematic review and meta-analysis2025
Effect of Time Delay on Reperfusion After Tenecteplase in an Extended Time Window: Analysis From the CHABLIS‐T Trials2025
Efficacy and safety of tenecteplase administration in extended time window for acute ischemic stroke: An updated meta-analysis of randomized controlled trials2025